alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Federal Register Volume 78, Number 130 (Monday, July 8, 2013)]
[Notices]
[Page 40821]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-16333]

-----------------------------------------------------------------------

DEPARTMENT OF STATE

[Public Notice 8373]

Bureau of Western Hemisphere Affairs, Executive Order 11423, as 
Amended; Notice of Receipt of Application for an Amendment to a 
Presidential Permit To Allow the Crossing of Non-Radioactive Hazardous 
Materials Across the World Trade Bridge in the City of Laredo, Texas

AGENCY: Department of State.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of State hereby gives notice that it has 
received an application for an amendment to the existing Presidential 
permit to allow the crossing of non-hazardous radioactive materials 
(HAZMAT) across the World Trade Bridge between the City of Laredo, 
Texas and Nuevo Laredo, Tamaulipas, Mexico. This application has been 
filed by the City of Laredo, the original permittee for the World Trade 
Bridge. A Presidential permit for the World Trade Bridge crossing was 
issued by the Department of State on October 7, 1994.
    The Department of State's jurisdiction with respect to this 
application is based upon the International Bridge Act of 1972, 33 
U.S.C. 535 et seq., and Executive Order 11423, dated August 16, 1968, 
as amended. The Department of State has determined that, under 
Executive Order 11423, an amended Presidential permit is required to 
allow the transit of HAZMATs as this constitutes a substantial change 
to the operations of the crossing as authorized by the existing 
Presidential permit.
    As provided in E.O. 11423, the Department is circulating the City 
of Laredo's application, along with the EA, to concerned agencies for 
comment. Under E.O. 11423, the Department has the responsibility to 
determine, taking into account input from these agencies and other 
stakeholders, whether issuance of an amendment to the Presidential 
Permit would serve the national interest.
    Interested members of the public are invited to submit written 
comments regarding this application on or before August 7, 2013 to 
MexicoCrossingComm@State.gov or to Peter Marigliano, Border Affairs 
Officer, WHA/MEX, HST Room 1329A, Department of State, 2201 C St. NW., 
Washington, DC 20520.

FOR FURTHER INFORMATION CONTACT: Peter Marigliano, Border Affairs 
Officer, WHA/MEX, HST Room 1329A, Department of State, 2201 C St. NW., 
Washington, DC 20520. Telephone: (202) 647-9895, email: WHA-BorderAffairs@state.gov.

SUPPLEMENTARY INFORMATION: The application and related documents are 
available for review in the Office of Mexican Affairs, Border Affairs 
Unit, Department of State, during normal business hours throughout the 
comment period. Any questions related to this notice may be addressed 
to Mr. Marigliano using the contact information above.

    Dated: June 27, 2013.
Hugo F. Rodriguez,
Acting Director, Office of Mexican Affairs, Department of State.
[FR Doc. 2013-16333 Filed 7-5-13; 8:45 am]
BILLING CODE 4710-29-P
```
# C_2022362EN.01000201.xml

| 21.9.2022 | EN | Official Journal of the European Union | C 362/2 |
| --- | --- | --- | --- |

21.9.2022

EN

Official Journal of the European Union

C 362/2

---

Euro exchange rates (1)

20 September 2022

(2022/C 362/02)

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 0,9986 |
| JPY | Japanese yen | 143,34 |
| DKK | Danish krone | 7,4368 |
| GBP | Pound sterling | 0,87395 |
| SEK | Swedish krona | 10,8338 |
| CHF | Swiss franc | 0,9644 |
| ISK | Iceland króna | 140,90 |
| NOK | Norwegian krone | 10,2730 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 24,556 |
| HUF | Hungarian forint | 398,58 |
| PLN | Polish zloty | 4,7208 |
| RON | Romanian leu | 4,9340 |
| TRY | Turkish lira | 18,2833 |
| AUD | Australian dollar | 1,4893 |
| CAD | Canadian dollar | 1,3268 |
| HKD | Hong Kong dollar | 7,8382 |
| NZD | New Zealand dollar | 1,6908 |
| SGD | Singapore dollar | 1,4074 |
| KRW | South Korean won | 1 390,71 |
| ZAR | South African rand | 17,7261 |
| CNY | Chinese yuan renminbi | 7,0030 |
| HRK | Croatian kuna | 7,5198 |
| IDR | Indonesian rupiah | 14 997,82 |
| MYR | Malaysian ringgit | 4,5516 |
| PHP | Philippine peso | 57,497 |
| RUB | Russian rouble | |
| THB | Thai baht | 36,968 |
| BRL | Brazilian real | 5,2139 |
| MXN | Mexican peso | 19,9667 |
| INR | Indian rupee | 79,6095 |

Currency

Exchange rate

USD

US dollar

0,9986

JPY

Japanese yen

143,34

DKK

Danish krone

7,4368

GBP

Pound sterling

0,87395

SEK

Swedish krona

10,8338

CHF

Swiss franc

0,9644

ISK

Iceland króna

140,90

NOK

Norwegian krone

10,2730

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

24,556

HUF

Hungarian forint

398,58

PLN

Polish zloty

4,7208

RON

Romanian leu

4,9340

TRY

Turkish lira

18,2833

AUD

Australian dollar

1,4893

CAD

Canadian dollar

1,3268

HKD

Hong Kong dollar

7,8382

NZD

New Zealand dollar

1,6908

SGD

Singapore dollar

1,4074

KRW

South Korean won

1 390,71

ZAR

South African rand

17,7261

CNY

Chinese yuan renminbi

7,0030

HRK

Croatian kuna

7,5198

IDR

Indonesian rupiah

14 997,82

MYR

Malaysian ringgit

4,5516

PHP

Philippine peso

57,497

RUB

Russian rouble

THB

Thai baht

36,968

BRL

Brazilian real

5,2139

MXN

Mexican peso

19,9667

INR

Indian rupee

79,6095

---

(1)  Source: reference exchange rate published by the ECB.

---
<PAGE>


                                                                 Exhibit 23.2


                     CONSENT OF INDEPENDENT ACCOUNTANTS


The Board of Directors
Anika Therapeutics, Inc.:

We consent to incorporation by reference in the registration statement 
(No. 33-66831) on Form S-8 of Anika Therapeutics, Inc. of our report dated 
February 18, 1998, relating to the balance sheet of Anika Therapeutics, Inc. 
as of December 31, 1997, and the related statements of operations, 
stockholders' equity, and cash flows for the year ended December 31, 1997, 
the four-month transitional period ended December 31, 1996 and the fiscal 
year ended August 31, 1996, which report appears in the December 31, 1998 
annual report on Form 10-K of Anika Therapeutics, Inc.



                                               KPMG Peat Marwick LLP



Boston, Massachusetts
March 31, 1999
HomeEspañol...Respecto a la muerte del presidente iraní Raisi y otros en una colisión de helicóptero

# 									Respecto a la muerte del presidente iraní Raisi y otros en una colisión de helicóptero							

Traducciones en español

20  de mayo de  2024

DEPARTAMENTO DE ESTADO DE EE. UU.DECLARACIÓN DE PRENSAMATTHEW MILLER, PORTAVOZ20 DE MAYO DE 2024

Estados Unidos expresa su condolencia oficial por el fallecimiento del presidente iraní Ebrahim Raisi, del ministro de Asuntos Exteriores Amir-Abdollahian, y de otros miembros de su delegación, en una colisión de un helicóptero en el noroeste de Irán. Al Irán seleccionar un nuevo presidente, reafirmamos nuestro apoyo al pueblo iraní en su lucha por los derechos humanos y las libertades fundamentales.

Para ver el texto original, ir a: https://www.state.gov/on-the-death-of-iranian-president-raisi-and-others-in-a-helicopter-crash/

*Esta traducción se proporciona como una cortesía y únicamente debe considerarse fidedigna la fuente original en inglés.*

Back to Top
<PAGE>
                                                                               .
                                                                               .
                                                                               .
                                                                     Exhibit 21


<TABLE>
<CAPTION>
NAME OF SUBSIDIARY                                              JURISDICTION OF ORGANIZATION
---------------------------------------------------------       --------------------------------
<S>                                                            <C>
Fidelity Chemical Products Malaysia SDN.BHD                     Malaysia
OM Holdings, Inc.                                               Delaware
OMG Americas, Inc.                                              Ohio
OMG Asia-Pacific Co., Ltd.                                      Taiwan
OMG Belleville, Limited                                         Canada
OMG Europe GmbH                                                 Germany
OMG Fidelity, Inc.                                              Delaware
OMG Finland Oy                                                  Finland
OMG Harjavalta Chemicals Holding BV                             Netherlands
OMG Harjavalta Nickel Oy                                        Finland
OMG Japan, Inc.                                                 Japan
OMG Jett, Inc.                                                  Ohio
OMG Kokkola Chemicals Holding BV                                Netherlands
OMG Kokkola Chemicals Oy                                        Finland
OMG Chemicals Pte, Ltd.                                         Singapore
OMG Thailand Co., Ltd.                                          Thailand
OMG Vasset, S.A.                                                France
Harko CV                                                        Netherlands
Groupement Pour Le Traitement Du teril De Lubumbashi (55%)      Jersey
Societe De Traitement du Terril De Lubumbashi (55%)             Democratic Republic of Congo
OMG Cawse Pty Ltd.                                              Australia
OMG U.K. Limited                                                United Kingdom
OMG KG Holdings, Inc.                                           Delaware

</TABLE>
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<ARTICLE>                     5
       
<S>                           <C>
<PERIOD-TYPE>                 6-mos
<FISCAL-YEAR-END>             Dec-31-1997
<PERIOD-END>                  Jun-30-1997
<CASH>                        1,933,504
<SECURITIES>                  000
<RECEIVABLES>                 000
<ALLOWANCES>                  000
<INVENTORY>                   000
<CURRENT-ASSETS>              000
<PP&E>                        000
<DEPRECIATION>                000
<TOTAL-ASSETS>                1,933,504
<CURRENT-LIABILITIES>         1,243,816
<BONDS>                       000
<COMMON>                      000
<PREFERRED-MANDATORY>         000
<PREFERRED>                   000
<OTHER-SE>                    668,938
<TOTAL-LIABILITY-AND-EQUITY>  1,933,504
<SALES>                       000
<TOTAL-REVENUES>              166,934
<CGS>                         000
<TOTAL-COSTS>                 000
<OTHER-EXPENSES>              621,371
<LOSS-PROVISION>              000
<INTEREST-EXPENSE>            000
<INCOME-PRETAX>               (454,437)
<INCOME-TAX>                  339,059
<INCOME-CONTINUING>           (182,397)
<DISCONTINUED>                000
<EXTRAORDINARY>               000
<CHANGES>                     000
<NET-INCOME>                  (182,397
<EPS-PRIMARY>                 (5.30)
<EPS-DILUTED>                 (5.30)
        

</TABLE>
(logo) BERKADIA®

 

 

Annual Statement as to Compliance

For the Year Ended December 31, 2023 (the “ReportingPeriod”)

 

*Benchmark 2021-B26 Mortgage Trust Commercial MortgagePass-Through Certificates,*

*Series 2021-B26*

 

 

Pursuantto Section 3.01 (f) of the Subservicing Agreement governing the referencedtransaction (the “Servicing Agreement”), as an authorized officer of BerkadiaCommercial Mortgage LLC (“Berkadia”), I hereby attest that:

 

i.                    A review of the activities and performanceof Berkadia as Subservicer during the Reporting Period has been made under mysupervision.

 

ii.                  To the best of my knowledge, based on suchreview, Berkadia as Subservicer has fulfilled, in all material respects, itsobligations under this Subservicing Agreement throughout the Reporting Periodand no default by the Subservicer under the Subservicing Agreement has occurredand is continuing.

              

 BerkadiaCommercial Mortgage LLC,

 

 

 /s/Mark E. McCool

MarkE. McCool

President

February10, 2024
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JUL-01-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                         115,189
<SECURITIES>                                         0
<RECEIVABLES>                                   15,336
<ALLOWANCES>                                       951
<INVENTORY>                                      6,791
<CURRENT-ASSETS>                               141,293
<PP&E>                                          30,705
<DEPRECIATION>                                   6,977
<TOTAL-ASSETS>                                 236,861
<CURRENT-LIABILITIES>                           10,026
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,150
<OTHER-SE>                                     222,169
<TOTAL-LIABILITY-AND-EQUITY>                   236,861
<SALES>                                         76,806
<TOTAL-REVENUES>                                76,806
<CGS>                                           18,069
<TOTAL-COSTS>                                   18,069
<OTHER-EXPENSES>                                    32
<LOSS-PROVISION>                                   342
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 29,520
<INCOME-TAX>                                    15,601
<INCOME-CONTINUING>                             13,919
<DISCONTINUED>                                  18,768
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    32,687
<EPS-PRIMARY>                                     1.12
<EPS-DILUTED>                                     1.12
        

</TABLE>
§ 1238.4 Methodologies and practices. ( a ) *Potential impact.* Except as noted in this subpart, in conducting a stress test under § 1238.3, each Enterprise shall calculate how each of the following is affected during each quarter of the stress test planning horizon, for each scenario: ( 1 ) Potential losses, pre-provision net revenues, and future pro forma capital positions over the planning horizon; and
( 2 ) Capital levels and capital ratios, including regulatory capital and net worth, and any other capital ratios specified by FHFA.
( b ) *Planning horizon.* Each Enterprise must use a planning horizon of at least nine quarters over which the impact of specified scenarios would be assessed.
( c ) *Additional analytical techniques.* If FHFA determines that the stress test methodologies and practices of an Enterprise are deficient, FHFA may determine that additional or alternative analytical techniques and exercises are appropriate for an Enterprise to use in identifying, measuring, and monitoring risks to the financial soundness of the Enterprise, and require an Enterprise to implement such techniques and exercises in order to fulfill the requirements of this part. In addition, FHFA will issue guidance annually to describe the baseline and severely adverse scenarios, and methodologies to be used in conducting the annual stress test.
( d ) *Controls and oversight of the stress testing processes.* ( 1 ) The appropriate senior management of each Enterprise must ensure that the Enterprise establishes and maintains a system of controls, oversight, and documentation, including policies and procedures, designed to ensure that the stress testing processes used by the Enterprises are effective in meeting the requirements of this part. These policies and procedures must, at a minimum, describe the Enterprise's testing practices and methodologies, validation and use of stress test results, and processes for updating the Enterprise's stress testing practices consistent with relevant supervisory guidance;
( 2 ) The board of directors, or a designated committee thereof, shall review and approve the policies and procedures established to comply with this part as frequently as economic conditions or the condition of the Enterprise warrants, but at least annually; and
( 3 ) Senior management of the Enterprise and each member of the board of directors shall receive a summary of the stress test results.
[85 FR 16530, Mar. 24, 2020]
Editorial Note on Part 1102
Editorial Note: Nomenclature changes to part appear at 83 FR 43739, Aug. 28, 2018.

§ 1102.6 Notice and comment. ( a ) The ASC shall publish promptly in the Federal Register a notice respecting: ( 1 ) A received Request for Temporary Waiver (*see* § 1102.3(c)); or
( 2 ) An ASC Order initiating a temporary waiver proceeding (*see* § 1102.5).
( b ) The notice of a received Request for Temporary Waiver or ASC Order initiating a temporary waiver proceeding shall contain a concise statement of the nature and basis for the action and shall give interested persons 30 calendar days from its publication in which to submit written data, views, and arguments.
<TABLE> <S> <C>

<ARTICLE>       5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM (A)
CONDENSED CONSOLIDATED BALANCE SHEET AT JUNE 30, 1998, CONDENSED CONSOLIDATED
INCOME STATEMENT FOR SIX MONTHS ENDED JUNE 30, 1998, AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH (B)
</LEGEND>
<MULTIPLIER> 1
<CURRENCY> U.S. Dollars
       
<S>                   <C>
<PERIOD-TYPE>         6-MOS
<FISCAL-YEAR-END>                Dec-31-1998
<PERIOD-START>                   Jan-01-1998
<PERIOD-END>                     Jun-30-1998
<EXCHANGE-RATE>                            1
<CASH>                             1,603,863
<SECURITIES>                               0
<RECEIVABLES>                      7,366,945
<ALLOWANCES>                         198,729
<INVENTORY>                          128,103
<CURRENT-ASSETS>                   9,664,019
<PP&E>                             8,689,729
<DEPRECIATION>                     3,846,929
<TOTAL-ASSETS>                    19,932,725
<CURRENT-LIABILITIES>              7,651,466
<BONDS>                            2,483,276
<COMMON>                              43,768
<PREFERRED-MANDATORY>                      0
<PREFERRED>                                0
<OTHER-SE>                         8,869,775
<TOTAL-LIABILITY-AND-EQUITY>      19,932,725
<SALES>                           15,166,544
<TOTAL-REVENUES>                  15,166,544
<CGS>                              2,564,802
<TOTAL-COSTS>                     10,055,022
<OTHER-EXPENSES>                   4,547,976
<LOSS-PROVISION>                           0
<INTEREST-EXPENSE>                   140,338
<INCOME-PRETAX>                      423,208
<INCOME-TAX>                         254,000
<INCOME-CONTINUING>                  169,208
<DISCONTINUED>                             0
<EXTRAORDINARY>                            0
<CHANGES>                                  0
<NET-INCOME>                         169,208
<EPS-PRIMARY>                            .05
<EPS-DILUTED>                            .05
        

</TABLE>
Home2023 Certificates of Competency for Nominees to be Chiefs of Mission...Rood, Elizabeth – Turkmenistan – January 2023

# 									Rood, Elizabeth – Turkmenistan – January 2023							

Certificate of Competency

January 23, 2023

UNITED STATES SENATE

SUBJECT: Ambassadorial Nomination: Certificate ofDemonstrated Competence — Foreign ServiceAct, Section 304(a)(4)

POST:                  Turkmenistan

CANDIDATE:      Elizabeth Rood

Elizabeth Rood, a career member of the Senior Foreign Service with the rank of Minister-Counselor, is the Deputy Chief of Mission, and currently Chargé d’Affaires, a.i., at the U.S. Embassy in Moscow, Russia.  Before that, she served as a Faculty Advisor at the U.S. Army War College.  Previously, she served as Deputy Chief of Mission at the U.S. Embassy in Tbilisi, Georgia, much of that time as Chargé d’Affaires, a.i.  Prior to that, she was Political Counselor at the U.S. Embassy in Kabul, Afghanistan.  Earlier, Rood directed the State Department’s Office of Export Control Cooperation in the Bureau of International Security and Nonproliferation, the Office of Caucasus Affairs and Regional Conflicts in the Bureau of European and Eurasian Affairs, and the Foreign Service Institute’s Stability Operations Division.  Additionally, she served as Principal Officer at the U.S. Consulate General in Peshawar, Pakistan.  In earlier assignments, she served as the State Department’s representative on the U.S. Provincial Reconstruction Team in Paktika Province in southeastern Afghanistan, as well as Deputy to the U.S. Special Negotiator for the Nagorno-Karabakh, Abkhazia, South Ossetia, and Transnistria conflicts.  Previous assignments include the Nonproliferation Bureau; the U.S. Mission to the International Organizations in Vienna, Austria; the U.S. Consulate General in Duesseldorf, Germany; and U.S. Embassies in Vienna, Austria, and Moscow, Russia.  Rood’s demonstrated success as a leader, coupled with nearly three decades of Foreign Service experience including previous regional experience, make her a well-qualified candidate to serve as U.S. Ambassador to Turkmenistan.

Rood is the recipient of numerous State Department performance awards, including three Senior Foreign Service Performance Awards.  A native of North Carolina, she holds an MA from the University of Maryland and an AB from Randolph-Macon Woman’s College.  She speaks French, Russian, German, Pashto, Dari, and Georgian.

Back to Top
FEB-06-2008 i•:29 SOLVAY SOLEXIS, [NC 856 85• 6405 P.OI 

FROM 

Total Pages including cover: Z CON•ibl:NTIAL 

-• Info Requested Fi For Your Information 

[] Will call to discuss [] Hard copy to follow by mail 

OJ3 I Lo l 0 7S- 6D- I 

Solvay Solexis, Inc. 

The New 

Standard in 

Fluorochemistry 

SOLEF® 

HALAR® ECTFE 

HYLAR • PVDF 

HYLAR 5000® PVDF 

HYFLON® MFA/PFA 

ALGOFLON® PTFE 

POLYMIST® PTFE 

TECNOFLON® 

FOMBLINe PFPE 

FLUOROLINK®PFPE 

GALDEN® PFPE 

H-GALDEN®HFPE 

VATAR ® 

Visit us at our website: 

www.solvaysolexis.com 

OR 

emaih solvaysolexisinfo@solvay.com 

Tel: 856-853.8119 

Main Fax: 856-853-6405 

Sales Fax: 856-384-6126 
FEB-06-2008 16:29 SOLUAY SOLEXIS, INC 856 853 6405 P.02 

Chemical. Ident•ty: 

Specific: 

• P99-4_•_•_Q•: [Ethene, tetrafluoro-, oxidized, polymd., reduced, decarboxylated, C• fraction][CAS RN 274917-93-0] 

P99-I_409: [Ethene, tetrafluoro-, oxidized, polymd., reduced, decarboxYlated, C 4 fraction][CAS RN 274917-94-1] 

p99-14•9: [Ethene, tetrafluoro-, oxidized, polymd., reduced, decarboxylated, Cs fraction][CAS •N 274917-95-2] 

[Ethene, tetrafluoro-, oxidized, polymd., reduced, decarboxylated, C 6 fraction][CAS RN 274917-96-3] 

P99-1412: [Ethene, tetrafluoro-, oxidized, polymd., reduced, decarbox•lated, C• fraction][CAS RN 274917-97-4] 

P99-141•: [Ethene, tetrafluoro-,oxidlzed, polymd., reduced, decarboxylated, C• fractlon][CAS RN 274918-01-3] 

P99•1414: [Ethene, tetrafluoro-,oxidized, polymd., reduced, decarboxylated, C9 fraction][CAS RN 274918-02-4] 

P99-1415: [Ethene, tetrafluoro-, oxidized, polymd., reduced, decarboxylated, C•0 fraction][CAS RN 274918-03-5] 

P99-1416: [Ethene, tetrafluoro-, oxidized, polymd., reduced, decarboxylated, C11 fraction][CAS RN 274918-09-1] 

P99-I•17: [Ethene, tetrafluoro-, oxidized, polymd., reduced, decarboxylated, C•a fraction][CAS RN 274918-10-4] 

P99-1418: [Ethene, tetrafluoro-, oxidized, polymd., reduced, decarboxylated, C• fraction][CAS RN 274918-12-6] 

Generic: Halogenated alkyl ether oligomers. 

TOTAL P. 02